预约演示

Crown Bioscience, HanX pact shows promise of lymphoma drug

2023-08-24

临床申请临床1期

HX009 has already undergone phase 1 studies in Australia and China for both solid tumor and lymphoma indications.

HX009artnership between preclinical services firm Crown Bioscience and HanX solid tumoruticalymphomawing promise for the Chinese biotech’s investigational drug to treat lymphoma.

A recent preclinical study of HanX’s HX009—which tCrown Biosciencelit tHanX Biopharmaceuticalndicated the bispecific antibody has a strong affinity towards binding to PDlymphoma weaker affinity to CD47. This characteristic allows better targeting to the tumor microenvironment and minimizes potential hematological toxicity, Crown said in an August 22 release.

"These Crown Bioscience studieHanXayeHX009—whichant rFDA in supporting the application of HX009 for the treatment of lymphoma in clinical trials," the CRO said. "They PD-1 played an instrumental roCD47n supporting the clearance of HanX’s FDA investigatiotumorew drug application, which has paved the way for a U.S.-based phase 1/2 clinical study that will assess HX009 in the treatment of relapsed/refractory lymphoma."

HX009 hCrown Biosciencegone phase 1 studies in Australia and China for solid tumors and lyHX009a. Now, HanX has its elymphomapanding clinical development into additional indications.HanX HX009 relapsed/refractory lymphoma

HX009n Bioscience consistently invests in expanding the number and divesolid tumorsels flymphomadevelopHanX, ensuring that our models accurately represent the relevant clinical disease biology and provide a solid foundation for making informed decisions about novel therapeutics such as HanX's HX009," Ludovic Bourre, Ph.D., Crown's vice president of research and innovation, said in the release.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构